Wilson Ramos replaces Joe Mauer and makes some history with four-hit debut

1 Comment

Joe Mauer is out for at least a few days with a heel injury, so the Twins called up 22-year-old prospect Wilson Ramos from Triple-A and he went 4-for-5 against the Indians yesterday in his big-league debut.
Ramos ranked No. 3 on my list of the Twins’ top prospects heading into the season, but was hitting just .179 with a poor 15/3 K/BB ratio in 16 games at Triple-A prior to the call-up. That makes his 4-for-5 debut pretty surprising, but even more amazing is that he’s the first player in 12 years to have a four-hit debut.
Better yet, I’m guessing 99.9 percent of baseball fans couldn’t name the last guy to do it. I certainly couldn’t, at least not before diving into Baseball-Reference.com for the answer. Go ahead, take your best guess. OK, ready? The answer is …
Derrick Gibson.
Exactly.
Gibson made his big-league debut for the Rockies on September 8, 1998 and went 4-for-4 in an 11-10 win over the Marlins. At the time he was only 23 years old, but Gibson played a grand total of just 16 more games in the majors, going 10-for-45 (.222), and was finished as a big leaguer the next season. He went on to spend 14 seasons in the minors before retiring in 2006.
Along with Ramos and Gibson, the other four-hit debuts belong to: Delino DeShields, Bill Bean, Kirby Puckett, Ted Cox, Mack Jones, Willie McCovey, Spook Jacobs, Cecil Travis, Russ Van Atta, Art Shires. That’s a pretty mixed bag, because for every star like Puckett, McCovey, and Travis there’s a Gibson, Bean, Cox, and Jacobs who essentially did nothing in the majors after their big debut.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.